Confocal Laser Endomicroscopy for the Diagnosis of Urothelial Carcinoma in the Bladder and the Upper Urinary Tract: Protocols for Two Prospective Explorative Studies

Esmee Iml Liem, Jan Erik Freund, Joyce Baard, D Martijn de Bruin, M Pilar Laguna Pes, C Dilara Savci-Heijink, Ton G van Leeuwen, Theo M de Reijke, Jean Jmch de la Rosette, Esmee Iml Liem, Jan Erik Freund, Joyce Baard, D Martijn de Bruin, M Pilar Laguna Pes, C Dilara Savci-Heijink, Ton G van Leeuwen, Theo M de Reijke, Jean Jmch de la Rosette

Abstract

Background: Visual confirmation of a suspicious lesion in the urinary tract is a major corner stone in diagnosing urothelial carcinoma. However, during cystoscopy (for bladder tumors) and ureterorenoscopy (for tumors of the upper urinary tract) no real-time histopathologic information can be obtained. Confocal laser endomicroscopy (CLE) is an optical imaging technique that allows for in vivo high-resolution imaging and may allow real-time tumor grading of urothelial lesions.

Objective: The primary objective of both studies is to develop descriptive criteria for in vivo CLE images of urothelial carcinoma (low-grade, high-grade, carcinoma in situ) and normal urothelium by comparing CLE images with corresponding histopathology.

Methods: In these two prospective clinical trials, CLE imaging will be performed of suspicious lesions and normal tissue in the urinary tract during surgery, prior to resection or biopsy. In the bladder study, CLE will be performed in 60 patients using the Cystoflex UHD-R probe. In the upper urinary tract study, CLE will be performed in 25 patients during ureterorenoscopy, who will undergo radical treatment (nephroureterectomy or segmental ureter resection) thereafter. All CLE images will be analyzed frame by frame by three independent, blinded observers. Histopathology and CLE-based diagnosis of the lesions will be evaluated. Both studies comply with the IDEAL stage 2b recommendations.

Results: Presently, recruitment of patients is ongoing in both studies. Results and outcomes are expected in 2018.

Conclusions: For development of CLE-based diagnosis of urothelial carcinoma in the bladder and the upper urinary tract, a structured conduct of research is required. This study will provide more insight in tissue-specific CLE criteria for real-time tumor grading of urothelial carcinoma.

Trial registration: Confocal Laser Endomicroscopy: ClinicalTrials.gov NCT03013894; https://ichgcp.net/clinical-trials-registry/NCT03013894?term=NCT03013894&rank=1 (Archived by WebCite at http://www.webcitation.org/6wiPZ378I); and Dutch Central Committee on Research Involving Human Subjects NL55537.018.15; https://www.toetsingonline.nl /to/ccmo_search.nsf/fABRpop?readform&unids=6B72AE6EB0FC3C2FC125821F001B45C6 (Archived by WebCite at http://www.webcitation.org/6wwJQvqWh). Confocal Laser Endomicroscopy in the upper urinary tract: ClinicalTrials.gov NCT03013920; https://ichgcp.net/clinical-trials-registry/NCT03013920? term=NCT03013920&rank=1 (Archived by WebCite at http://www.webcitation.org/6wiPkjyt0); and Dutch Central Committee on Research Involving Human Subjects NL52989.018.16; https://www.toetsingonline.nl/to/ccmo_search.nsf/fABRpop?readform&unids=D27C9C3E5755CFECC12581690016779F (Archived by WebCite at http://www.webcitation.org/6wvy8R44C).

Keywords: biopsy; confocal laser endomicroscopy; nephroureterectomy; nonmuscle invasive bladder carcinoma; optical imaging; segmental ureter resection; transurethral resection bladder tumor; upper urinary tract carcinoma; ureterorenoscopy; urothelial cancer grading; urothelial carcinoma.

Conflict of interest statement

Conflicts of Interest: None declared.

©Esmee IML Liem, Jan Erik Freund, Joyce Baard, D Martijn de Bruin, M Pilar Laguna Pes, C Dilara Savci-Heijink, Ton G van Leeuwen, Theo M de Reijke, Jean JMCH de la Rosette. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 07.02.2018.

Figures

Figure 1
Figure 1
Cellvizio CLE (Confocal laser endomicroscopy) system and the probes used for the urinary tract. (A) Cellvizio CLE system; (B) The two different probes used in the urinary tract. On the left the Cystoflex UHD-R probe with a diameter of 2.6 mm, which is used in the bladder. On the right the Uroflex-B probe with a diameter of 0.85 mm, which is used in the upper urinary tract; (C) RAW image of the Cystoflex UHD-R probe displaying the single fibers; (D) RAW image of the Uroflex-B probe displaying the single fibers.
Figure 2
Figure 2
A schematic overview of the data analysis plan. CLE: confocal laser endomicroscopy; PA: histopathology.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30. doi: 10.3322/caac.21387. doi: 10.3322/caac.21387.
    1. Cina S, Epstein JL, Endrizzi JM, Harmon WJ, Seay TM, Schoenberg MP. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol. 2001 Jun;32(6):630–7. doi: 10.1053/hupa.2001.24999.
    1. Rouprêt Morgan, Babjuk M, Compérat Eva, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero Paolo, Van Rhijn Bas W G, Mostafid A Hugh, Palou J, Shariat SF. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2018 Jan;73(1):111–122. doi: 10.1016/j.eururo.2017.07.036.
    1. Dunbar KB, Okolo P 3rd, Montgomery E, Canto MI. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc. 2009 Oct;70(4):645–54. doi: 10.1016/j.gie.2009.02.009.
    1. He XK, Liu D, Sun LM. Diagnostic performance of confocal laser endomicroscopy for optical diagnosis of gastric intestinal metaplasia: a meta-analysis. BMC Gastroenterol. 2016 Sep 05;16:109. doi: 10.1186/s12876-016-0515-3.
    1. Wijmans L, d'Hooghe JN, Bonta PI, Annema JT. Optical coherence tomography and confocal laser endomicroscopy in pulmonary diseases. Curr Opin Pulm Med. 2017 May;23(3):275–283. doi: 10.1097/MCP.0000000000000375.
    1. Wu K, Liu JJ, Adams W, Sonn GA, Mach KE, Pan Y, Beck AH, Jensen KC, Liao JC. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology. 2011 Jul;78(1):225–31. doi: 10.1016/j.urology.2011.02.057.
    1. Chang TC, Liu JJ, Hsiao ST, Pan Y, Mach KE, Leppert Jt, McKenney JK, Rouse RV, Liao JC. Interobserver agreement of confocal laser endomicroscopy for bladder cancer. J Endourol. 2013 May;27(5):598–603. doi: 10.1089/end.2012.0549.
    1. Bui D, Mach KE, Zlatev DV, Rouse RV, Leppert JT, Liao JC. A Pilot Study of In Vivo Confocal Laser Endomicroscopy of Upper Tract Urothelial Carcinoma. J Endourol. 2015 Dec;29(12):1418–23. doi: 10.1089/end.2015.0523.
    1. Villa L, Cloutier J, Cotè JF, Salonia A, Montorsi F, Traxer O. Confocal Laser Endomicroscopy in the Management of Endoscopically Treated Upper Urinary Tract Transitional Cell Carcinoma: Preliminary Data. J Endourol. 2016 Feb;30(2):237–42. doi: 10.1089/end.2015.0644.
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315–30.
    1. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006 Sep;68(3):549–53. doi: 10.1016/j.urology.2006.03.062.
    1. Fowler CG, Boorman LS. Outpatient treatment of superficial bladder cancer. Lancet. 1986 Jan 04;1(8471):38.
    1. Wedderburn AW, Ratan P, Birch BR. A prospective trial of flexible cystodiathermy for recurrent transitional cell carcinoma of the bladder. J Urol. 1999 Mar;161(3):812–4.
    1. El-Hakim A, Weiss GH, Lee BR, Smith AD. Correlation of ureteroscopic appearance with histologic grade of upper tract transitional cell carcinoma. Urology. 2004 Apr;63(4):647–50; discussion 650. doi: 10.1016/j.urology.2003.10.076.
    1. Vashistha V, Shabsigh A, Zynger DL. Utility and diagnostic accuracy of ureteroscopic biopsy in upper tract urothelial carcinoma. Arch Pathol Lab Med. 2013 Mar;137(3):400–7. doi: 10.5858/arpa.2012-0136-OA.
    1. Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012 Sep;110(5):614–28. doi: 10.1111/j.1464-410X.2012.11068.x. doi: 10.1111/j.1464-410X.2012.11068.x.
    1. Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED Jr, Sosa RE. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol. 2000 Jan;163(1):52–5.
    1. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug;70(2):252–6. doi: 10.1016/j.urology.2007.03.051.
    1. Straub J, Strittmatter F, Karl A, Stief CG, Tritschler S. Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma. Urol Oncol. 2013 Oct;31(7):1166–70. doi: 10.1016/j.urolonc.2011.12.021.
    1. Williams SK, Denton KJ, Minervini A, Oxley J, Khastigir J, Timoney AG, Keeley FX Jr. Correlation of upper-tract cytology, retrograde pyelography, ureteroscopic appearance, and ureteroscopic biopsy with histologic examination of upper-tract transitional cell carcinoma. J Endourol. 2008 Jan;22(1):71–6. doi: 10.1089/end.2007.9853.
    1. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, Nicholl J, Balliol Collaboration. Aronson JK, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Feldman LS, Flum DR, Maddern GJ, Nicholl J, Reeves BC, Seiler CM, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Ergina PL, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Meakins J, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009 Sep 26;374(9695):1105–12. doi: 10.1016/S0140-6736(09)61116-8.
    1. Wallace M, Meining A, Canto MI, Fockens P, Miehlke S, Roesch T, Lightdale CJ, Pohl H, Carr-Locke D, Löhr M, Coron E, Filoche B, Giovannini M, Moreau J, Schmidt C, Kiesslich R. The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract. Aliment Pharmacol Ther. 2010 Mar;31(5):548–52. doi: 10.1111/j.1365-2036.2009.04207.x. doi: 10.1111/j.1365-2036.2009.04207.x.
    1. Sonn GA, Jones SN, Tarin TV, Du CB, Mach KE, Jensen KC, Liao JC. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol. 2009 Oct;182(4):1299–305. doi: 10.1016/j.juro.2009.06.039.
    1. Moosbrugger KA, Sheidow TG. Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein. Can J Ophthalmol. 2008 Oct;43(5):571–5. doi: 10.3129/i08-122.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel